Biblio
A
Schneider M, Rolfs C, Trumpp M, Winter S, Fischer L, Richter M, Menger V, Nenoff K, Grieb N, Metzeler KH, et al. Activation of distinct inflammatory pathways in subgroups of LR-MDS. Leukemia. 2023.
I
Polverelli N, Bonneville EF, de Wreede LC, Koster L, Kröger NMartin, Schroeder T, de Latour RPeffault, Passweg J, Sockel K, Broers AEC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. 2024.
M
von Dalowski F, Kramer M, Wermke M, Wehner R, Röllig C, Alakel N, Stölzel F, Parmentier S, Sockel K, Krech M, et al. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory GvHD: Clinical Responses and Long-Term Outcome. Stem Cells. 2015.
O
Ortí G, Gras L, Zinger N, Finazzi MChiara, Sockel K, Robin M, Forcade E, Avenoso D, Kröger N, Finke J, et al. Outcomes after Allogeneic Hematopoietic Cell Transplant in patients diagnosed with Blast Phase of Myeloproliferative Neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2023.
R
Stelljes M, Middeke JMoritz, Bug G, Wagner-Drouet E-M, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024.